Methamphetamine alters vesicular monoamine transporter-2 function and potassium-stimulated dopamine release.

Journal of Neurochemistry
Pei-Wen ChuAnnette E Fleckenstein

Abstract

This report demonstrates that a repeated 'challenge' high-dose methamphetamine (METH) injection regimen rapidly decreases striatal K(+)-stimulated dopamine (DA) release concurrent with decreases in both synaptosomal membrane-associated (referred to herein as membrane-associated) and previously reported decreases in non-synaptosomal membrane-associated (presumably cytoplasmic) vesicular DA uptake and content. Resembling previously reported effects involving cytoplasmic vesicles wherein uptake was decreased 48 h after treatment, the decrease in membrane-associated uptake persisted 72 h. Cytoplasmic and membrane-associated vesicular DA uptakes were decreased 7 days after the challenge regimen. A single METH injection also rapidly decreased K(+)-stimulated DA release, membrane-associated DA content, and membrane-associated DA uptake; however, unlike after the challenge regimen, the decrease in uptake recovered by 24 h. Pre-treatment with the D(2) receptor antagonist, eticlopride, did not attenuate the decrease in membrane-associated uptake as assessed 1 h after either a single or challenge treatment. However, eticlopride attenuated the decrease in membrane-associated uptake caused by the challenge regimen as assessed 24 h later. Th...Continue Reading

References

Jun 28, 1992·Annals of the New York Academy of Sciences·D SulzerS Rayport
May 1, 1989·Brain Research·W L WoolvertonL S Seiden
Apr 29, 1999·Journal of Neuroscience Research·A H StokesK E Vrana
Mar 16, 2000·Reviews in the Neurosciences·D Sulzer, E N Pothos
May 9, 2000·Journal of Neurochemistry·J M BrownA E Fleckenstein
Mar 7, 2001·The American Journal of Psychiatry·N D VolkowE N Miller
Jul 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jeffrey M BrownAnnette E Fleckenstein
Aug 7, 2002·European Journal of Pharmacology·Evan L RiddleAnnette E Fleckenstein
Feb 27, 2003·The Journal of Pharmacology and Experimental Therapeutics·Verónica SandovalAnnette E Fleckenstein
Jun 16, 2005·Progress in Neurobiology·David SulzerAurelio Galli
Aug 9, 2007·Journal of Neurochemistry·David J Eyerman, Bryan K Yamamoto
Aug 19, 2007·The Journal of Pharmacology and Experimental Therapeutics·Trent J VolzAnnette E Fleckenstein
Jul 5, 2008·European Journal of Pharmacology·Pei-Wen ChuAnnette E Fleckenstein
Nov 29, 2008·The Journal of Pharmacology and Experimental Therapeutics·Sarah J FarnsworthAnnette E Fleckenstein
Jan 15, 2009·The Journal of Pharmacology and Experimental Therapeutics·Gregory C HadlockAnnette E Fleckenstein
Jul 14, 2010·The Journal of Pharmacology and Experimental Therapeutics·Gregory C HadlockAnnette E Fleckenstein

❮ Previous
Next ❯

Citations

Oct 13, 2015·Progress in Neurobiology·Rosario MoratallaMicaela Morelli
Nov 29, 2011·Synapse·Lisa M McFaddenAnnette E Fleckenstein
Apr 23, 2013·Journal of Internal Medicine·S Ares-SantosR Moratalla
Jan 9, 2014·Neurochemistry International·Alison I BernsteinGary W Miller
Sep 27, 2015·Pharmacological Reviews·Christopher L GermanAnnette E Fleckenstein
Jul 20, 2019·The Journal of Pharmacology and Experimental Therapeutics·Nicholas B MinerAaron Janowsky

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.